PAID DISCOVERY™ · PRE-DEVELOPMENT SCIENTIFIC DUE DILIGENCE
Paid Discovery is a prepaid, science-first decision gate run by an open, zero-conflict CDMO. We map the biological system, test each candidate against dose-, form-, and population-matched human evidence, select raw materials for the brief rather than from stock, and screen safety with the interaction logic applied to medicines. You receive controlled documents and one explicit decision: proceed, redesign, pause, or stop.
BIOLOGICAL SYSTEMS MAP · PROJECT-SPECIFIC RAW MATERIALS · DRUG-STYLE INTERACTION SCREEN · CONTROLLED DECISION
This action routes to the written scoped quote intake. It does not promise a free strategy call, direct CEO consultation, or unlimited messaging.
WHAT IT IS
A prepaid professional scope that tests the scientific, legal, safety, and physical logic of a product before bench, pilot, or production spend.
WHAT YOU RECEIVE
A controlled report, formula card, and decision record, with the evidence, claims, safety, and feasibility material the locked brief requires.
WHAT MAKES IT DIFFERENT
Raw materials selected for the project rather than from stock, dose-matched human evidence, and a toxicology, CYP450, transporter, and interaction review written for a prescribing physician.
HOW IT ENDS
PROCEED, REDESIGN UNDER NEW SCOPE, PAUSE, or STOP. A documented stop is a valid professional result, not a failure of the service.
Interest in our services is exceptionally high. Through 31 December 2026, we may not be able to reply individually to every enquiry. Paid Discovery is offered selectively: we assess projects—not people—against their scope, scientific needs, commercial readiness, and fit with our current capabilities.
WHY THIS IS NOT WHAT EVERYONE DOES
From the outside, most development offers look alike. The difference is who carries the evidence, the safety logic, and the manufacturing consequence, and whether the process is allowed to say no.
In practice there are two coherent routes. Generic private label is built for speed and price from what is already in stock. A full CDMO such as Olympia is built for differentiation and for efficacy evidence matched to the exact material, dose, and population, without a closed catalogue of raw materials or packaging. Choose the route that matches what your brand has to prove.
QUESTION
TYPICAL FREE PRIVATE-LABEL FORMULA
TYPICAL INDEPENDENT CONSULTANT
OLYMPIA PAID DISCOVERY™
STARTING POINT
TYPICAL FREE PRIVATE-LABEL FORMULA
Ingredients the supplier already stocks
TYPICAL INDEPENDENT CONSULTANT
Preferred ingredients or a literature summary
OLYMPIA PAID DISCOVERY™
A biological systems map of the intended function before any ingredient is considered
RAW MATERIALS
TYPICAL FREE PRIVATE-LABEL FORMULA
Selected from a closed warehouse catalogue
TYPICAL INDEPENDENT CONSULTANT
Recommended without sourcing or manufacturing accountability
OLYMPIA PAID DISCOVERY™
Selected for the brief; every formula direction names at least one differentiating raw material with evidence matched to the product and market
EVIDENCE
TYPICAL FREE PRIVATE-LABEL FORMULA
Supplier sheets and category convention
TYPICAL INDEPENDENT CONSULTANT
Evidence summaries, often without dose or form matching
OLYMPIA PAID DISCOVERY™
Human evidence matched for source, form, dose, population, and endpoint, with null and contradictory findings kept visible
SAFETY
TYPICAL FREE PRIVATE-LABEL FORMULA
Label and maximum-level check
TYPICAL INDEPENDENT CONSULTANT
General safety commentary
OLYMPIA PAID DISCOVERY™
Toxicology, CYP450, transporter, drug-interaction, synergy, and antagonism review across the whole intended-use system
CLAIMS
TYPICAL FREE PRIVATE-LABEL FORMULA
Generic claims reused across markets
TYPICAL INDEPENDENT CONSULTANT
Advice that may stop at one jurisdiction
OLYMPIA PAID DISCOVERY™
A claims and prohibited-language matrix for every named jurisdiction
MANUFACTURABILITY
TYPICAL FREE PRIVATE-LABEL FORMULA
Whatever the existing line already runs
TYPICAL INDEPENDENT CONSULTANT
Not tested against a production system
OLYMPIA PAID DISCOVERY™
Theoretical galenic feasibility assessed by a CDMO that operates its own production infrastructure
CONFLICT OF INTEREST
TYPICAL FREE PRIVATE-LABEL FORMULA
May compete with you through its own brands
TYPICAL INDEPENDENT CONSULTANT
Independent, but without production responsibility
OLYMPIA PAID DISCOVERY™
Pure-play B2B: no competing consumer brands
END STATE
TYPICAL FREE PRIVATE-LABEL FORMULA
A formula designed to lead to a production order
TYPICAL INDEPENDENT CONSULTANT
A report
OLYMPIA PAID DISCOVERY™
Controlled documents and an explicit decision, including STOP
PORTABILITY
TYPICAL FREE PRIVATE-LABEL FORMULA
Formula often tied to the supplier
TYPICAL INDEPENDENT CONSULTANT
Varies by engagement
OLYMPIA PAID DISCOVERY™
Every contracted deliverable is yours on full payment and portable to any manufacturer
The comparison describes common market patterns, not any named company. Individual suppliers and consultants may work differently.
NO LOCK-IN
Everything created for your project in Paid Discovery is contracted to you: once paid in full, the deliverables are yours to use and portable, and you may take them, with the quality already designed into the product, to any manufacturer. Only Olympia’s background know-how, templates, tools, and AI workflows stay with us. We do not rely on lock-in; we would rather earn the production order.
WHY THE RESULT IS HARD TO COPY
Much of the market formulates from raw materials already in stock, because stock has to be sold. Olympia starts from the evidence. Paid Discovery selects the raw material the brief needs; when the project proceeds, that material is bought for your project, even if it means importing a single kilogram from the other side of the world. A product built from what every warehouse already holds can be copied by anyone who holds it. A brand needs something the shelf does not already offer.
Efficacy evidence is specific. It applies to a defined population and age, a defined matrix, form, and dose, in a defined region of the world. A closed raw-material catalogue cannot promise that match for every brief. That is why every product of this kind starts with Paid Discovery: it tests whether the match exists, and says so when it does not.
01
OPEN TO THE GLOBAL MARKET
If a new raw-material form with materially better bioavailability or stronger evidence reaches the global market, it can enter your project, provided its evidence, legal status, and feasibility hold in your target market.
02
DEPTH INSTEAD OF SCALE
Project-specific materials remove the warehouse shortcut. Each one needs its own evidence match, admissibility check, and safety review, and small project lots cost more than stock. That is why this work is an individually scoped, paid analysis, and why the result cannot simply be reordered by someone else.
03
DIFFERENTIATION YOU CAN DEFEND
The differentiating raw material is chosen together with the evidence behind it, so the difference can be explained to regulators, physicians, and buyers, not only to marketing.
Paid Discovery selects the raw material on evidence. Sourcing, supplier qualification, minimum order quantities, and the cost of the selected materials are confirmed in the separately scoped next stage.
THE CORE OF THE METHOD
Olympia combines an open raw-material model, medicine-style interaction screening, and zero consumer-brand conflict inside one controlled decision process.
PROJECT-SPECIFIC RAW MATERIALS
Olympia purchases raw materials per project order rather than working from a closed warehouse, so discovery can follow the evidence to the source, form, and grade the product needs. Every formula direction names at least one differentiating raw material, with efficacy evidence matched to the product, the brief, and the target market. Sourcing and supplier qualification follow as a separately scoped stage.
PHYSICIAN-GRADE SAFETY SCAN
Every formula direction carries a toxicology review, a CYP450 and transporter interaction screen, and an in-silico interaction and antagonism review, extended to relevant medicines, vulnerable populations, and combined use. It is written so a prescribing physician can follow the reasoning and its limits. Where no clinically relevant signal is found, the record says so and states that this is not proof of absence.
ZERO-CONFLICT CDMO
Olympia does not operate competing consumer brands. Your brief, formula direction, and evidence remain inside a B2B relationship governed by the signed agreement and a certified ISO/IEC 27001 information-security management system. Contracted deliverables become portable after full payment.
WHAT YOU RECEIVE
Paid Discovery gives your team a defensible scientific, regulatory, safety, technical, and commercial foundation before physical development starts. The exact controlled artifacts are selected according to the contracted category, population, markets, delivery system, product portfolio, and risk profile.
The work begins with biological equations, cross-condition mechanisms, feedback, timing, measurable endpoints, and over-targeting risk before a component enters the candidate pool.
Each active is tested against human evidence for its exact source, form, dose, population, duration, and endpoint. Double-blind randomised controlled trials are prioritised where they exist, the match class and remaining gaps are stated, and every reference is cited with title, authors, year, journal, and DOI.
Every accepted and rejected candidate is traceable through the screening sequence, including status-pathway, allergen, claims, safety, and jurisdiction barriers that would otherwise surface too late.
The dossier maps what can and cannot be said in each contracted jurisdiction, including health-claim constraints, warning language, and the public-label implications of the selected actives.
The risk architecture covers individual and organ-system toxicology, positive synergy, antagonism, within-product and cross-product interactions, cumulative exposure, medicines, CYP450, relevant transporters, vulnerable populations, monitoring, and stop conditions.
Olympia maps the theoretical fit of the actives into the chosen dosage form, including flowability, hygroscopicity, density, excipient logic, and clean-label constraints before laboratory work begins.
The deliverables package includes the formula card with precise mass architecture and directional feasibility notes, including preliminary manufacturability assumptions and non-binding COGS direction.
Each brief ends with a governed decision: PROCEED, REDESIGN UNDER NEW SCOPE, PAUSE, or STOP, plus the exact next paid route if practical validation, external verification, pilot, or production planning is justified.
OWNERSHIP & PRODUCTION CREDIT
After full payment, the contracted Paid Discovery deliverables are portable and may be shared with another manufacturer. Olympia reusable tools, templates, general methods, AI workflows, and background know-how remain outside the deliverable.
EARNED MANUFACTURING CREDIT
Only the net paid Paid Discovery Core base fee per SKU is eligible for Manufacturing Credit under the signed schedule; Market-Ready, jurisdiction, additional-round and all other add-on modules are excluded. The eligible Core amount may unlock in 50% tranches at the first and second qualifying commercial production POs for the same SKU. Credit is conditional, non-cash and non-refundable, subject to the Finance-approved contribution-margin cap, and never automatic.
HOW THE DECISION IS BUILT
The scientific spine is consistent, but the module manifest changes with the product category, population, named countries, delivery system, portfolio structure, and risk profile. Paid Discovery determines what the concept survives before practical validation, external testing, pilot work, or production commitments begin.
AI-ASSISTED RESEARCH · SOURCE-AUDITED DECISIONS
AI-assisted search expands the reachable literature and regulatory surface; it does not become the scientific authority. Material conclusions are tied to primary or authoritative sources, exact form and exposure, null and contradictory findings, an independent review step, and an explicit evidence boundary.
Why We Cannot Provide Production Quotes Without This Process.
A spreadsheet can accept an incoherent product. A permitted component or accepted filing does not establish scientific integrity, finished-product efficacy, absence of interactions, or industrial feasibility. We therefore separate due diligence from production pricing and require the relevant decision gates before practical execution.
RESEARCH SERVICES · METHODOLOGICAL SUPPORT
Where a programme needs a stronger evidence package, Paid Discovery can define the methodological support for literature reviews used in evidence-based scientific assessments: research-question framing, inclusion and exclusion logic, evidence hierarchy, endpoint relevance, contradiction logging and dossier-ready synthesis for the locked brief.
PHASE 1
We convert the intended function into biological equations: compartments, cells, receptors, enzymes, transporters, feedback loops, timing, measurable endpoints, and over-targeting risk. No ingredient enters the candidate pool until the causal system is defined.
Mechanism map · over-targeting risks · measurable endpoints
PHASE 2
We temporarily leave the consumer category and search other fields for the same causal architecture. Candidate routes are then tested for human exposure, target access, dose, source, form, and functional relevance, while null and contradictory evidence remains visible.
Cross-condition map · Master Evidence Pool · translational verdicts
PHASE 3
Candidates pass through the scientific, source, category, jurisdiction, allergen, certification, dosage-form, stability, safety, and commercial gates activated by the signed brief. Every elimination and unresolved condition remains auditable.
Screening audit · conditional routes · rejected and unresolved register
PHASE 4
We determine the product route and what may lawfully be communicated in every named country. Science, legal status, and claimability remain separate, so an authorised claim never substitutes for biological fit.
Country-by-country pathway · claims and prohibited-language matrix · warning inputs
PHASE 5
We assign each component a defined role, verify its source, form, and evidence-supported exposure, and test the quantitative architecture against the intended delivery system, use pattern, and multi-product system. Decorative inclusion is rejected.
Controlled product architecture · dose and role justification · removal priority
PHASE 6
We examine individual and organ-system toxicology, intended synergy, antagonism, within-product interactions, and cumulative exposure across every product intended for combined use. The review extends to relevant medicines, CYP450, conjugation enzymes, transporters, vulnerable populations, timing, monitoring, and stop conditions.
Safety dossier · synergy/antagonism · multi-product exposure · drug/CYP/transporter review
PHASE 7
The selected architecture is tested against the physics and chemistry of the actual delivery system: mass or phase balance, solubility, flow or rheology, compatibility, degradation, packaging, analytical readiness, and missing material data.
Theoretical feasibility verdict · risk matrix · physical validation plan
PHASE 8
Every contracted conclusion is tied to a controlled artifact, source set, reviewer, version, limitation, and decision. The release states whether to proceed, redesign, pause, or stop, and identifies the separately paid physical or regulatory work required next.
Controlled deliverables register · decision record · next work-order map
The same name does not establish the same product: source, form, standardisation, process, matrix, route, exposure, population, and use pattern can all change the scientific, safety, legal, and technical conclusion. Paid Discovery records those boundaries before they become expensive physical errors.
HOW THE EVIDENCE IS STRUCTURED
Every Paid Discovery follows the same requirement catalogue; only the number of products, raw materials, and contracted markets changes. Conclusions are built upward and never inferred from a generic ingredient statement. A region such as “EU” or “GCC” resolves into named countries before analysis.
01
LEVEL R · RAW MATERIAL × MARKET
For each raw material in each contracted market: exact identity and form, dose and whole-product exposure, evidence for that form and dose, legal and dose admissibility, permitted claims and conditions of use, warnings, toxicology, interactions, and alternatives when a route is blocked.
02
LEVEL P · PRODUCT × MARKET
The product inherits only what its ingredients support in that market at that dose, unless a product-level authorisation applies. A product claim is permitted only when its ingredients or a product-level authorisation support it, product warnings are at least the union of ingredient warnings, and certification status follows the weakest component.
03
LEVEL D · CONTROLLED DOCUMENTS
Controlled documents are issued from the product rows, each with its source set, version, limitations, and dependent decisions. A product conclusion cannot be marked complete while any raw-material row it depends on remains open.
STAGE BOUNDARY
Specifications, COA and source-lock requirements, the testing plan, stability protocol, shelf-life rationale, per-market labels, and the registration route are delivered through the Market-Ready pre-PO package. Lot COAs, finished-product results, real-time stability data, and batch release belong to Stage II and are never simulated in Paid Discovery.
CONTROLLED SCIENTIFIC DOCUMENTATION
Paid Discovery is not a recommendation hidden inside a presentation. Depending on the contracted category, population, markets, delivery system, portfolio, and risk profile, Olympia Biosciences issues a controlled documentation stack that makes the reasoning, source authority, limitations, and next decision auditable.
01
Defines the causal system, enabling physiology, feedback, timing, and over-targeting risk before candidate discovery.
02
Preserves source, form, dose, population, duration, and endpoint fit together with null and contradictory findings.
03
Records why each route was accepted, conditioned, held, varied by market, or rejected.
04
Separates product category, component status, lawful communication, conditions of use, and warnings country by country.
05
Links each component role and quantitative use to the biological, legal, safety, and delivery-system constraints.
06
Distinguishes intended cooperation from absorption competition, receptor or enzyme opposition, timing conflicts, and untested hypotheses.
07
Treats every product intended for combined use as one exposure and interaction system.
08
Maps clinically relevant medication classes, enzyme and transporter direction, evidence strength, management, and uncertainty.
09
Examines material organ-system signals with use controls, monitoring, and escalation rules.
10
Summarises medication context, monitoring, washout or surgery considerations, stop conditions, and known evidence boundaries when professional review is relevant.
11
States what appears physically plausible and what bench, stability, analytical, or pilot evidence is still required.
12
Provides source authority, reviewer, version, lifecycle status, limitations, and dependent decisions for every contracted artifact.
HOW DOCUMENTS ARE ISSUED
Controlled documents are issued as versioned files through an authenticated client portal or another authorised channel, indexed so every contracted artifact can be located. A chat answer, working file, or portal paragraph never substitutes for a controlled document.
EVIDENCE BOUNDARY
Documentary and in-silico assessment does not establish finished-product clinical efficacy, prove the absence of all interactions, verify batch purity, demonstrate bioavailability, substantiate shelf life, validate an industrial process, or guarantee authority acceptance. Those questions require the corresponding clinical, analytical, stability, regulatory, or practical work order.
FOUR VALID END STATES
Every Paid Discovery ends with a Decision Record and the next-stage path. Each outcome is a complete professional answer to the locked brief, not a guaranteed regulatory, technical, clinical, or commercial result.
PROCEED
The concept survives the scientific, legal, safety, and theoretical feasibility gates. The record names the separately scoped physical, analytical, or regulatory work that comes next.
REDESIGN UNDER NEW SCOPE
The objective is viable, but not in the briefed form. The record states what must change and why; the redesign is scoped as new work.
PAUSE
A decisive input is missing: evidence, material data, a legal position, or a client decision. The record names the blocker and what would reopen the route.
STOP
The route cannot be defended. You learn this before bench, pilot, packaging, or production spend, with the reasons documented.
QUESTIONS TO ASK ANY DEVELOPMENT PARTNER
Authorised claims are set for defined substances under defined conditions of use. They do not require evidence on how ingredients behave together in one formula, how bioavailable they are in that matrix, or whether they remain stable after processing. A product can meet every legal requirement and still fail to deliver. Ask these questions of any development partner, including us.
01
WHICH MATERIAL, WHICH STUDY?
Which exact extract, plant part, standardisation, or strain does each ingredient use, and which human studies used that same material? Two extracts sold under one botanical name can carry different evidence, and probiotic effects are strain-specific.
In Paid Discovery: Dose-Matched Evidence Dossier
02
WHAT CANCELS WHAT?
Which ingredients in this formula compete for absorption, antagonise each other, or compete as live cultures? More ingredients can mean less effect.
In Paid Discovery: Synergy & Antagonism Matrix
03
WHAT HAPPENS WITH MEDICINES?
Where is the CYP450, transporter, and drug-interaction review for this specific formula and its intended users, not for each ingredient in isolation?
In Paid Discovery: Drug, CYP450 & Transporter Review
04
WHAT REACHES THE PATIENT?
How will oxidation, degradation, and stability be proven on the finished product rather than on the incoming raw material?
In Paid Discovery: Theoretical Feasibility & Validation Plan
Quality is designed into the process, not tested in at the end. Paid Discovery defines what must be tested and why; finished-product stability and analytical data are generated in the separately scoped Stage II.
THE PROBLEM WE SOLVE
Before development-facing work is authorised, Paid Discovery tests the causal biological model, evidence transfer, product category, named jurisdictions, quantitative exposure, toxicology, synergy, antagonism, multi-product use, medicines, CYP450 and transporters, vulnerable populations, delivery-system constraints, stability risk, and documentation readiness.
A supplier catalogue, competitor label, automated claim check, or spreadsheet cannot resolve these risks. They require a source-audited decision process that keeps negative evidence, uncertainty, and stop conditions visible.
An authorised claim, permitted component, positive ingredient study, or plausible mechanism does not prove the finished product. Legal communication, biological fit, human exposure, safety, technical feasibility, and finished-product evidence remain separate questions.
READ: COMMON FORMULATION ERRORS →PROJECT-SPECIFIC MODULE MANIFEST
The method is consistent; the activated work is not generic. Product category, population, delivery system, every named country, source requirements, certifications, and multi-product use determine which analyses and controlled artifacts the project requires.
PRODUCT ROUTE
Supplement · FSMP / medical nutrition · functional food · cosmetic · oral care · borderline
POPULATION
Healthy · paediatric · older adult · clinical · pregnancy exclusions · professional supervision
DELIVERY SYSTEM
Solid oral · powder · liquid · emulsion · gummy · softgel · food matrix · topical · oral-care matrix
JURISDICTION
Every contracted country is assessed separately; a region is not treated as one legal system
SOURCE & CERTIFICATION
Activated only when required: allergen, halal, kosher, vegan, organic, extraction solvent, origin, source lock
PORTFOLIO
Single product or cumulative multi-product system with combined-use scenarios
The published per-product entry applies to eligible supplement projects. FSMP, medical nutrition, oral care, cosmetic, borderline, and other bespoke programmes are individually scoped. The scientific method is universal; the legal, technical, documentation, and commercial route is not.
BASE UNIT — PROFESSIONAL SCOPE ONLY
Paid Discovery Core is a Stage I professional scope only: one SKU, one format, one objective, one target population, one named standard jurisdiction, up to five active ingredients, two consolidated review rounds, and a report, formula card, and decision record. It does not include physical execution, sourcing, laboratory work, or actual Stage II batch records, COAs, batch test or stability results, or release.
STARTING FEE
FROM EUR 4,500
One supplement SKU, one dosage format, one objective, one target population, and one standard supplement jurisdiction.
ACTIVE LIMIT
UP TO 5 ACTIVES
The public base fee covers no more than five active ingredients. Excipients do not count unless they need separate scientific or regulatory justification.
REVIEW BOUNDARY
2 CONSOLIDATED ROUNDS
Exactly two consolidated review rounds from one authorised client representative are included in the professional fee.
PAYMENT GATE
100% PREPAID
Work starts only after cleared payment, completed intake, and signed scope lock. No subjective holdback applies to commencement.
LOCKED BASE UNIT
1 SKU / 1 FORMAT
The public base unit is one SKU in one dosage format. Each further SKU or format is scoped and quoted separately.
PRACTICAL WORK
SEPARATELY SCOPED
Bench work, samples, analytics, stability, and pilot runs are not part of Paid Discovery; they start only under a separately scoped work order.
CONTRACTED DELIVERABLES
The professional fee covers the contracted report, formula card, and decision record for the locked supplement brief. The package may include the mechanism map, dose-matched evidence, toxicology screen, claims matrix, screening audit trail, and directional feasibility notes required to support the final recommendation. Completion means delivery of those artifacts and response to two valid consolidated rounds — not a guaranteed regulatory, technical, clinical, or commercial outcome.
GOVERNED ADD-ON LOGIC
There are no hidden discounts and no silent expansions of the base fee. Named jurisdictions, technology class, active count, and complexity are priced before signature. Ingredients 6–10 add EUR 250 each. Ingredients 11–15 add EUR 400 each after the first tier. Each additional standard jurisdiction adds EUR 1,200. Complex jurisdictions start from EUR 2,500 and require manual confirmation. Market-Ready pre-PO adds EUR 4,000. An additional consolidated round is EUR 750 per affected SKU. Each materially different objective or population adds EUR 500; each additional formula architecture adds EUR 1,000; dossier rescue adds EUR 750; novel-status investigation adds EUR 300 each. Eligible same-family additional SKUs receive 35% off their full quote only under the defined matching conditions. More than 15 active ingredients requires manual scientific review.
ACTIVE INGREDIENTS 6–10
+ EUR 250 EACH
Use this tier only after the base five active ingredients are exhausted.
ACTIVE INGREDIENTS 11–15
+ EUR 400 EACH
This second tier applies after the 6–10 ingredient surcharge has already been added.
ABOVE 15 ACTIVES
MANUAL SCIENTIFIC REVIEW
More than 15 active ingredients is outside the public calculator and requires manual scientific review before quoting.
ADDITIONAL STANDARD JURISDICTION
+ EUR 1,200 EACH
For an additional EU/EEA member state, the UK, or Switzerland.
COMPLEX JURISDICTION
+ FROM EUR 2,500 EACH
Surcharge per complex jurisdiction, added to the Paid Discovery fee only after manual confirmation. UAE, Saudi Arabia, other GCC states, and the USA require manual confirmation. Unlisted jurisdictions require manual classification before quoting.
MARKET-READY PRE-PO PACKAGE
+ EUR 4,000
Adds specifications, COA/source-lock requirements, a testing plan, a stability protocol, shelf-life rationale, per-jurisdiction labels, warnings and claims, and a registration route with required documents and certificates. A one-SKU, one-jurisdiction Core plus Market-Ready package totals EUR 8,500. Actual Stage II batch records, COAs, results, and release are excluded.
ADDITIONAL CONSOLIDATED REVIEW ROUND
+ EUR 750 PER AFFECTED SKU
Prepaid for each additional consolidated round beyond the two included rounds.
ELIGIBLE SAME-FAMILY ADDITIONAL SKU
35% OFF FULL QUOTE
Applies only with the same SoW, legal entity, format class, and jurisdiction set. The first SKU remains full price.
ADDITIONAL OBJECTIVE OR POPULATION
+ EUR 500
Applies to each materially different additional objective or target population.
ADDITIONAL FORMULA ARCHITECTURE
+ EUR 1,000
Applies to each additional formula architecture or scenario.
DOSSIER RESCUE
+ EUR 750
Applies when an existing dossier requires separately scoped rescue work.
NOVEL-STATUS INVESTIGATION
+ EUR 300 EACH
Each separately scoped novel-status investigation is priced per ingredient.
POWDER / SACHET / STICKPACK
+ EUR 750
Applies when the brief needs theoretical taste, dispersion, hygroscopicity, or stickpack architecture before any practical validation work order.
DEMANDING DELIVERY SYSTEMS
FROM EUR 1,500
Liquids, gummies, softgels, emulsions, liposomal systems, and other demanding formats require manual technical review before a final quote is issued.
SEPARATELY QUOTED UNDER THE CANONICAL MODEL
Additional technologies, materially different objectives or populations, new formula architectures, dossier rescue, special status-pathway investigations, and every new SKU are separately scoped. The 35% same-family discount applies only to an additional SKU under the same SoW, legal entity, format class, and jurisdiction set; the first SKU remains full price. Regions such as “EU” or “GCC” must resolve into named markets before quoting. FSMP, medical nutrition, and borderline-regulated products are routine premium Olympia capabilities, but do not enter this public supplement calculator. They proceed through bespoke scientific, regulatory, clinical, technical, and commercial scoping before an individual quotation; no public price, “from” price, calculator, automatic SoW, or automatic credit is created.
FSMP / MEDICAL NUTRITION
FSMP sits under Regulation (EU) No 609/2013 and Delegated Regulation (EU) 2016/128 rather than the standard supplement pathway. Standard supplement logic is invalid here. The route requires metabolic rationale, borderline-risk analysis, expanded drug-nutrient interaction review, and technical FSMP labeling constraints before quotation.
Olympia Biosciences™ prepares the scientific, regulatory, and legal substantiation package required to defend the route. That does not mean any responsible CDMO can guarantee in advance that a competent authority will ultimately accept the project as FSMP.
Metabolic Rationale
The brief must prove nutritional vulnerability and explain why the pathology requires a specific nutritional intervention rather than a standard wellness formulation.
Borderline Risk Dossier
The route must survive authority scrutiny around category boundaries, intended use, claims language, and the legal distinction from medicinal products.
Advanced Drug-Interaction Review
Nutrient-drug collisions, CYP/P450 pathways, contraindications, and therapy-specific risks are screened at a stricter level than the standard supplement route.
Technical FSMP Labeling
The route requires technical labeling language such as “for the dietary management of …” and physician-supervision wording rather than standard marketing claims.
NOT INCLUDED IN THE PROFESSIONAL FEE
NEXT SEPARATELY PAID STAGES
Used for physical formulation work such as prototypes, samples, flavour/sensory iterations, materials, sourcing, supplier qualification, and practical trials.
Used for accredited analytical, microbiological, contaminant, identity, potency, and other external laboratory verification.
Used for pilot batches, process confirmation, scale-up evidence, line parameters, and industrial execution planning.
Quoted separately under production economics, quality scope, and accepted commercial terms after the governed pre-production stages are complete.
A reliable manufacturing cost cannot be established from a product name alone. It depends on the formula and dosage system, product format, packaging requirements, batch scale, target-market and labelling needs, verification requirements and supply constraints. Olympia first defines the relevant technical and commercial inputs; a production quotation follows only when the scope is sufficiently specified.
Paid Discovery is the paid, bounded decision step for a supplement project. Physical validation, external testing, packaging procurement, supplier-validated COGS, pilot work and commercial production are separately scoped. FSMP and medical-nutrition programmes follow bespoke scoping and individual pricing.
PORTABILITY · RIGHTS · BESPOKE SCOPING
The paid report is portable and may be shared with another manufacturer. Olympia reusable tools, templates, general methods, AI workflows, and background know-how are not part of the deliverable. FSMP, medical nutrition, and borderline-regulated products follow Olympia’s bespoke scoping and quotation path outside the public supplement calculator. No automatic price, SoW, feasibility declaration, or Manufacturing Credit is created before confirmed scope.
Paid Discovery can conclude with PROCEED, REDESIGN UNDER NEW SCOPE, PAUSE, or STOP. The fee buys disciplined analysis and clear deliverables for the locked supplement brief — not a guaranteed external, regulatory, manufacturing, or commercial result.
Use the intake to lock the supplement brief, declare jurisdictions and actives, and receive the governed quote path. No free strategy call, no extended-scope additions, and no unqualified executive access are bundled into the base fee.
RELATED INTELLIGENCE